Residual Inflammatory Risk On Treatment with PCSK9 Inhibition and Statin Therapy

RECOMMENDED

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

JAMA Cardiol.

Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP

doi: 10.1001/jamacardio.2020.3151.

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy

J Am Heart Assoc.

Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, Riesmeyer JS, Weerakkody G, Ruotolo G, Cremer PC, Nicholls SJ, Lincoff AM, Nissen SE

doi: 10.1161/JAHA.119.014328.

Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.

Eur Heart J.

Langslet G

doi: 10.1093/eurheartj/ehw098.

RECOMMENDED

Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

J Am Heart Assoc

Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana JS, Wagner J, Philip S, Abrahamson D, Granowitz C, Go AS

doi: 10.1161/JAHA.120.020377

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs

Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis

JAMA Cardiol

Patel J, Pallazola VA, Dudum R, Greenland P, McEvoy JW, Blumenthal RS, Virani SS, Miedema MD, Shea S, Yeboah J, Abbate A, Hundley WG, Karger AB, Tsai MY, Sathiyakumar V, Ogunmoroti O, Cushman M, Savji N, Liu K, Nasir K, Blaha MJ, Martin SS, Al Rifai M

doi: 10.1001/jamacardio.2021.2321

Heart, Artery and Coronary Diseases

Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy

J Am Heart Assoc.

Hilvo M, Wallentin L, Ghukasyan Lakic T, Held C, Kauhanen D, Jylhä A, Lindbäck J, Siegbahn A, Granger CB, Koenig W, Stewart RAH, White H, Laaksonen R, STABILITY Investigators

doi: 10.1161/JAHA.119.015258.

RECOMMENDED

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Atherosclerosis.

Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L

doi: 10.1016/j.atherosclerosis.2020.07.006.

Hypertension

Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS

Hypertension.

Rothman AM, MacFadyen J, Thuren T, Webb A, Harrison DG, Guzik TJ, Libby P, Glynn RJ, Ridker PM

doi: 10.1161/HYPERTENSIONAHA.119.13642.

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy

Circ Cardiovasc Imaging.

Kwon O, Kang SJ, Kang SH, Lee PH, Yun SC, Ahn JM, Park DW, Lee SW, Kim YH, Lee CW, Han KH, Park SW, Park SJ

doi: 10.1161/

Related content

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial

Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy

Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study

Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis

Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy

Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies

Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS

Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy